Evaxion (NASDAQ: EVAX) files 6-K on Q2 2025 update and press release

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology powered vaccines, furnished a Form 6-K for August 2025. The filing mainly reports that on August 14, 2025 the company issued a press release titled "Evaxion announces business update and second quarter 2025 financial results," which is included as Exhibit 99.1. The Form 6-K is also incorporated by reference into multiple existing registration statements on Forms S-8, F-3 and F-1, allowing the information in this report to be used in those offering documents.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On August 14, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion announces business update and second quarter 2025 financial results". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits 

Exhibit No.		Description
99.1		Evaxion announces business update and second quarter 2025 financial results

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: August 14, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What does Evaxion A/S (EVAX) disclose in this Form 6-K?

The Form 6-K states that Evaxion A/S furnished a press release dated August 14, 2025 titled "Evaxion announces business update and second quarter 2025 financial results" as Exhibit 99.1, and that this report is incorporated by reference into several of its existing registration statements.

Which press release is attached to Evaxion A/S (EVAX) Form 6-K?

The filing attaches as Exhibit 99.1 a press release titled "Evaxion announces business update and second quarter 2025 financial results," issued by Evaxion A/S on August 14, 2025.

How is this Evaxion A/S (EVAX) Form 6-K used in existing registration statements?

The report on Form 6-K is incorporated by reference into Evaxion A/S’s registration statements on Form S-8, multiple Forms F-3, and several Forms F-1, so the information in this report becomes part of those offering documents unless superseded later.

Does the Form 6-K describe Evaxion A/S’s business focus?

Yes. It notes that Evaxion A/S is a clinical-stage TechBio company that specializes in developing AI-Immunology powered vaccines.

Who signed Evaxion A/S (EVAX) Form 6-K and in what capacity?

The Form 6-K was signed on behalf of Evaxion A/S by Birgitte Rønø, who is identified as the Interim Chief Executive Officer.